|File Size||53.4 KiB|
|Date||December 14, 2015|
|Author||Jakub Zavada, William G Dixon, Johan Askling and for the EULAR Study group on Longitudinal Observational Registers and Drug Studies|
The advent and increased use of targeted therapies in rheumatology have stimulated the establishment of clinical drug registers. Such registers have evaluated a broad spectrum of outcomes in patients exposed to these uniquely designed, potent and expensive drugs.1–8 Although the main focus of most drug registers in rheumatology is drug safety, other important issues include drug usage, real-life effectiveness and economic consequences.